BOSTON — Cambridge, Massachusetts-based Biogen has gotten the green light for a breakthrough ALS treatment that targets a devastating, ultra-rare genetic form of the progressive neurodegenerative disease. The U.S. Food and Drug Administration on Tuesday granted approval of Qalsody for the treatment of ALS in adults who have a mutation…Read More
Biogen receives FDA approval for breakthrough ALS treatment Pivotal moment in ALS research
